If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,681.00    20.00 (1.20%)
Bid:
1,680.00
Ask:
1,682.00
Spread: 2.00 (0.119%)
Market Cap: £3.54b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Holding(s) in Company

24 Jan 2022 12:45

RNS Number : 4069Z
Hikma Pharmaceuticals Plc
24 January 2022
 

TR-1: Standard form for notification of major holdings

 

 LONDLONDON, 24 January 2022 - Hikma Pharmaceuticals PLC (LEI:549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) announces as follows:

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Hikma Pharmaceuticals PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Details of person subject to the notification obligation

Name

The Capital Group Companies, Inc.

City and country of registered office (if applicable)

Los Angeles, USA

4. Full name of shareholder(s)  (if different from 3.)

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached:

20/01/2022

6. Date on which issuer notified (DD/MM/YYYY):

21/01/2022

7. Total positions of person(s) subject to the notification obligation:

 

% of voting rights attached to shares

(total of 8.A)

% of voting rights through financial instruments

(total of 8.B.1 + 8.B.2)

Total of both in %

(8.A + 8.B)

Total number of voting rights of issuer

Resulting situation on the date on which threshold was crossed or reached

4.92%

0.00%

4.92%

231,498,055

Position of previous notification (if applicable)

9.64%

0.00%

9.64%

 

       

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Voting rights attached to shares

Class/type of shares ISIN code (if possible)

Number of voting rights

% of voting rights

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00B0LCW083 Common Stock

 

11,385,712

 

4.92%

 

 

 

 

 

SUBTOTAL 8.A

11,385,712

4.92%

 

B 1: Financial Instruments DTR5.3.1R (1) (a)

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

N/A

 

 

 

 

 

 

SUBTOTAL 8.B.1

 

 

 

B 2: Financial Instruments with similar economic effect DTR5.3.1R (1) (b)

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Physical or cash settlement

Number of voting rights

% of voting rights

N/A

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

       

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer

 

Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)

X

Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Capital Research and Management Company

 

 

 

Total

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional information:

 

The Capital Group Companies, Inc. ("CGC") is the parent company of Capital Research and Management Company ("CRMC") and Capital Bank & Trust Company ("CB&T"). CRMC is a U.S.-based investment management company that serves as investment manager to the American Funds family of mutual funds, other pooled investment vehicles, as well as individual and institutional clients. CRMC and its investment manager affiliates manage equity assets for various investment companies through three divisions, Capital Research Global Investors, Capital International Investors and Capital World Investors. CRMC is the parent company of Capital Group International, Inc. ("CGII"), which in turn is the parent company of five investment management companies ("CGII management companies"): Capital International, Inc., Capital International Limited, Capital International Sàrl, Capital International K.K, and Capital Group Private Client Services, Inc. CGII management companies and CB&T primarily serve as investment managers to institutional and high net worth clients. CB&T is a U.S.-based investment management company that is a registered investment adviser and an affiliated federally chartered bank.

Neither CGC nor any of its affiliates own shares of your company for its own account. Rather, the shares reported on this Notification are owned by accounts under the discretionary investment management of one or more of the investment management companies described above.

 

 

 

Place of completion

Los Angeles

Date of completion

21/01/2022

       

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUSSURUAUAUAR
Date   Source Headline
6th Jul 20269:40 amRNSTransaction in Own Shares
1st Jul 202612:05 pmRNSTotal Voting Rights
29th Jun 20269:50 amRNSTransaction in Own Shares
22nd Jun 20261:11 pmRNSTransaction in Own Shares
15th Jun 202612:20 pmRNSHolding(s) in Company
15th Jun 20269:40 amRNSTransaction in Own Shares
12th Jun 20269:00 amRNSHolding(s) in Company
8th Jun 202610:00 amRNSTransaction in Own Shares
2nd Jun 202612:42 pmRNSDirector/PDMR Shareholding
1st Jun 20264:16 pmRNSTotal Voting Rights
1st Jun 202612:11 pmRNSTransaction in Own Shares
27th May 202610:05 amRNSTransaction in Own Shares
26th May 202610:30 amRNSTransaction in Own Shares
18th May 202610:55 amRNSTransaction in Own Shares
15th May 20269:45 amRNSChange of Registered Office
11th May 20261:10 pmRNSTransaction in Own Shares
6th May 20263:08 pmRNSDirector/PDMR Shareholding
5th May 20269:55 amRNSTransaction in Own Shares
1st May 202610:36 amRNSTotal Voting Rights
28th Apr 20261:29 pmRNSDirector/PDMR Shareholding
27th Apr 202611:55 amRNSTransaction in Own Shares
23rd Apr 20263:42 pmRNSResult of AGM
23rd Apr 20267:00 amRNSTrading Statement
20th Apr 202610:55 amRNSTransaction in Own Shares
13th Apr 20263:29 pmRNSDirector/PDMR Shareholding
13th Apr 202611:10 amRNSTransaction in Own Shares
9th Apr 20264:43 pmRNSDirector/PDMR Shareholding
7th Apr 20269:42 amRNSTransaction in Own Shares
1st Apr 202611:11 amRNSTotal Voting Rights
30th Mar 202610:55 amRNSTransaction in Own Shares
23rd Mar 202611:00 amRNSTransaction in Own Shares
18th Mar 202610:10 amRNSAnnual Financial Report and Notice of AGM
16th Mar 20269:29 amRNSTransaction in Own Shares
16th Mar 20269:29 amRNSTransaction in Own Shares
11th Mar 202610:09 amRNSDirector/PDMR Shareholding
11th Mar 202610:09 amRNSDirector/PDMR Shareholding
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20264:56 pmRNSTotal Voting Rights
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:05 amRNSLaunch of Buyback Programme
26th Feb 20267:00 amRNSFinal Results, Share Buyback & Leadership Changes
4th Feb 20265:29 pmRNSStatement regarding Hikma Pharmaceuticals Plc
3rd Feb 20267:00 amRNSNotice of Results
19th Dec 20253:50 pmRNSDirector/PDMR Shareholding
19th Dec 20253:50 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.